Sep 11, 2023 8:00am EDT Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting
Sep 07, 2023 8:00am EDT Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
Aug 14, 2023 4:00pm EDT Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update
Aug 01, 2023 8:00am EDT Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast
Jul 18, 2023 8:00am EDT Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting
Jul 11, 2023 11:23am EDT Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)
Jun 06, 2023 8:00am EDT Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
May 25, 2023 9:00am EDT Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
May 23, 2023 6:00am EDT Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
May 17, 2023 8:00am EDT Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank